Ragweed sublingual tablet immunotherapy: Part i - Evidence-based clinical efficacy and safety

Research output: Contribution to journalReview articlepeer-review


Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studies and the clinical outcomes from the pivotal trials which provide clear evidence for statistically significant and clinically meaningful benefit in the treatment of patients suffering from ragweed-induced seasonal allergic rhinitis-conjunctivitis with or without milder asthma. The robust results observed in the clinical trials performed with the ragweed sublingual tablet are defined by the quality of their study design, their use of a standardized allergen extract, their consistent reproducibility in demonstrating therapeutic efficacy and their properly quantified and graded safety data.

Original languageEnglish (US)
Pages (from-to)605-616
Number of pages12
Issue number7
StatePublished - Jun 2018


  • allergen immunotherapy
  • allergic rhinitis/conjunctivitis
  • ragweed
  • ragweed pollen
  • ragweed subcutaneous immunotherapy
  • ragweed sublingual immunotherapy
  • ragweed sublingual tablet

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Ragweed sublingual tablet immunotherapy: Part i - Evidence-based clinical efficacy and safety'. Together they form a unique fingerprint.

Cite this